Results 131 to 140 of about 24,184 (203)

Phage-meropenem synergy against OXA-48-producing Klebsiella pneumoniae clinical isolates. [PDF]

NPJ Antimicrob Resist
Cantallops I, Ferriol-González C, Barcos-Rodríguez T, Fernández-Cuenca F, Cañada-García JE, García-Cobos S, Domingo-Calap P.   +6 more
europepmc   +1 more source

Genomic and virulence characterization of OXA-48-producing <i>Klebsiella pneumoniae</i> causing urinary tract infections and their susceptibility to lytic bacteriophages. [PDF]

Front Microbiol
Rey S, Silva-Bea S, Davina-Nunez C, Romero M, Fontán-Silva B, Pérez S, Otero A.   +6 more
europepmc   +1 more source

Limits of rapid diagnostics: genomic and structural insights into OXA-48-like mediated carbapenem resistance in <i>Escherichia coli</i>. [PDF]

Front Microbiol
Diab AA, Jalal D, Fadel YM, Samir O, Shalaby L, Elanany M, Abo-Elmaaty SA, Aziz RK, Sayed AA, Hassan MG.   +9 more
europepmc   +1 more source

Unraveling Cefiderocol Resistance in NDM- and OXA-48-like Co-Producing <i>Klebsiella pneumoniae</i> Isolates Through Integrated Genomic and Phenotypic Analysis. [PDF]

Antibiotics (Basel)
Ambretti S, Cetatean R, Secci B, Landi J, Cantiani A, Foschi C.   +5 more
europepmc   +1 more source

Carbapenem and colistin-resistant <i>Klebsiella pneumoniae</i> co-producing NDM-5 and OXA-48 in a teaching hospital from Tunisia. [PDF]

JAC Antimicrob Resist
Jaidane N, Mansour W, Oueslati S, Mehidi I, Al Laham N, Lazzem A, Berriri A, Ben Lamine Y, Trabelsi A, Dortet L, Naija W, Bonnin RA, Iorga BI, Tilouche L, Naas T.   +14 more
europepmc   +1 more source

Effects of phage-based treatments against an OXA-48-producing Klebsiella pneumoniae isolate in simulated human gut microbiomes. [PDF]

BMC Microbiol
Ferriol-González C, Hernanz-Grimalt A, Valdivia C, García-Cobos S, Heredia A, García-Hernández J, Andrés A, Domingo-Calap P.   +7 more
europepmc   +1 more source

Role of Giannella and Increment Scores to Predict OXA-48 Carbapenemase Producing Enterobacterales Infection and Mortality in Previous Rectal Carriers. [PDF]

Open Forum Infect Dis
Martínez Pérez-Crespo PM, Cuevas-Corrales JL, Torres E, Rodríguez-Fernández M, Valverde-Fredet MD, Aller AI, Trigo-Rodríguez M, Espíndola-Gómez R, León E, García-Sánchez E, Luna-Jiménez TL, Herrero Del Río R, Fernández-Pevida A, Lanz-García JF, Valiente de Santis L, Corzo JE, Merchante N.   +16 more
europepmc   +1 more source

The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing <i>Enterobacterales</i> infections: a systematic review and meta-analysis. [PDF]

JAC Antimicrob Resist
Foo AL, Young B, Ng OT, Vasoo S.
europepmc   +1 more source

Electrostatic interactions influence diazabicyclooctane inhibitor potency against OXA-48-like β-lactamases. [PDF]

RSC Med Chem
Hoff JF, Goudar KE, Calvopiña K, Beer M, Hinchliffe P, Shaw JM, Tooke CL, Takebayashi Y, Cadzow AF, Harmer NJ, Mulholland AJ, Schofield CJ, Spencer J.   +12 more
europepmc   +1 more source

Continuous Infusion of Aztreonam-Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae. [PDF]

Infect Dis Ther
Laffont-Lozes P, Villa F, Mory C, Sotto A, Loubet P, Pantel A, Larcher R.   +6 more
europepmc   +1 more source